Evaxion A/S (EVAX) Discusses EVX-01 Phase II Clinical and Immune Data in Advanced Melanoma October 29, 2026 10:30 AM EDT Birgitte Rono - Chief Scientific Officer & COO Birgitte RonoChief Scientific Officer & COO I'm Birgitte Rono, CSO and COO at Evaxion. So on behalf…
Many patients with skin cancer who were treated with immune checkpoint inhibition experienced long-term side effects, although some resolved over time, research showed. Chronic immune-related side effects were common in patients with skin cancer who were treated with postsurgical Opdivo…
Dean Drobot via Canva Replimune Group (REPL) shares jumped 17% today on its first update on the TUDRIQEV melanoma launch. The launch reaches two bigger names. TUDRIQEV is an oncolytic virus, like Imlygic from Amgen (AMGN), and it’s given with Opdivo…
An experimental drug that Genmab gained in an $8 billion buyout succeeded in a late-stage trial in a form of head and neck cancer, sending shares of the Danish drugmaker soaring to an all-time high. At an early analysis, a combination…
Residual pigmentation after primary treatment and nonbulbar tumor involvement were associated with higher local recurrence risk, while ulceration and greater tumor thickness were linked to metastasis... Review of: Conjunctival melanocytic lesions: A practical sequential treatment approach Mastrogiuseppe E, Hussain R,…
SITC also invites you to attend the virtual press briefing of the society's 41st Annual Meeting (SITC 2026) beginning at 12–1:30 p.m. MT on Wednesday, Nov. 4, 2026. The schedule of presentations and press briefing presenters are listed in order below: Abstract #553: Adoptive transfer of…
Clinical data for first combination of two T cell engagers in a solid tumor will be presented in a poster on Friday, November 6, and an oral presentation on November 7 The poster and oral presentations will include additional safety and efficacy…
Adding a personalised messenger RNA (mRNA) cancer vaccine to pembrolizumab — an immunotherapy drug — after surgery for high-risk melanoma reduced the risk of recurrence or death by 42%, phase III trial results have shown. During the trial — the results of which were…
Primary category: Clinical Trials In Progress Date and time: Saturday, November 7, 2026, 10:00 am - 2:00 pm and 6:00 pm - 8:10 pm MST The full abstract will be available as of 9:00 am EST on November 3, 2026, and will be published on the SITC website and in the…
Afamelanotide is effective, yet access, cost, and travel limit its use. The discussion considers adherence, the promise of oral therapies, and how dermatologists, hepatologists, and hematologists should share care. In "Melanocortin Therapy in EPP: Access, Adherence, and Multidisciplinary Care," our…
Melanoma, basal and squamous cell skin cancer: diagnosis, treatment, skin checks and sun protection.
An article joins this feed when it matches these terms. Each one is also a search of its own.